Table 6.

Immune-mediated adverse events in the durvalumab plus EP arm (n = 18)

	Any grade	Grade 3a	Intervention	Resolved
Any imAE, n (%)b	4 (22)	1 (6)	–	–
Hyperthyroidism	1 (6)	0	Endocrine therapy	Yes
Hypothyroidism	1 (6)	0	Endocrine therapy	No
Interstitial lung disease	1 (6)	0	Systemic corticosteroid/high-dose steroid	No
Type 1 diabetes mellitus	1 (6)	1 (6)	Endocrine therapy	No

No imAEs were reported among patients treated with EP alone

^aNo grade 4 imAEs were reported

^bAn immune-mediated adverse event was defined as an event that was associated with drug exposure and was consistent with an immune-mediated mechanism of action, where there was no clear alternate etiology and the event required treatment with systemic corticosteroids or other immunosuppressants and/or, for specific endocrine events, endocrine therapy

EP platinum-etoposide, imAE immune-mediated adverse event